Longr.io Logo - Your Guide to Longevity and Anti-Aging Science

Longevity Investments Skyrocket: OpenAI’s Altman Backs Retro Biosciences, Viome’s CVS Deal, & Genesis Therapeutics’ AI-Driven $200M Series B

Today, we're unravelling the mystery behind Retro Biosciences' massive $180 million backing (Hint: Think OpenAI). Meanwhile, Seattle's Viome Life Sciences is making headlines with a fresh $86.5 million Series C and an exciting CVS partnership. But that's not all … Dive in and discover how Genesis Therapeutics, with a cool $200 million Series B, is merging AI and biotech to redefine drug discovery.
Articles showcasing growth in longevity investment sectors.
Investing in Longevity: Financial Strategies for a Longer Life.

Good Morning,

Welcome to your Tuesday longevity investment digest – covering some of the allocations that are moving life extension towards reality.

Today, we’re unravelling the mystery behind Retro Biosciences’ massive $180 million backing (Hint: Think OpenAI). Meanwhile, Seattle’s Viome Life Sciences is making headlines with a fresh $86.5 million Series C and an exciting CVS partnership. But that’s not all … Dive in and discover how Genesis Therapeutics, with a cool $200 million Series B, is merging AI and biotech to redefine drug discovery.

With big names, bigger investments, and the biggest dreams, this edition is packed with the latest and greatest from the longevity investment frontier.

Let’s dive in …


Sam Altman invested $180 million into a company trying to delay death (MIT Technology Review)

In 2022, Retro Biosciences burst onto the scene, armed with a daring dream: add a cool ten years to human life. They flaunted a hefty $180 million in funding, but kept everyone guessing about the deep pockets behind it.

The mystery’s out. The stash came from none other than Sam Altman, the youthful 37-year-old mastermind behind OpenAI.

Retro Biosciences is diving deep into the world of anti-aging, drawing inspiration from the trailblazing “young blood” studies…

a16z-backed AI biotech startup Genesis Therapeutics raises $200 million (Crunchbase)

Genesis Therapeutics, combining artificial intelligence with biotech, have just bagged a whopping $200 million in their Series B funding.

The round was led by Andreessen Horowitz and another mystery U.S. life-sciences investor. Big names like Fidelity Management & Research Co., BlackRock, and Nvidia’s NVentures have also jumped on board.

Based in Burlingame, California, Genesis’ mission is to harness AI to supercharge drug discovery. With this fresh influx of cash, they’re gearing up to enter the clinical stage, beef up their AI tech, and widen their discovery horizons.

Seattle-based longevity start-up, Viome Life Sciences, closes $86.5 million Series C (GeekWire)

From the heart of Seattle, Viome Life Sciences has just bagged a cool $86.5 million in their Series C round. What’s more? They’re partnering up with CVS pharmacies, rolling out their ground-breaking gut microbiome test across 200 stores coast to coast.

Brainchild of the entrepreneur Naveen Jain and backed by the glitz of Paris Hilton as both investor and brand ambassador, Viome is making waves with at-home kits that dive deep into stool samples, dishing out dietary insights, supplements, and probiotics.

In collaboration with the renowned Los Alamos National Laboratory, they’ve already delved into over 600,000 samples. But, word on the street? The medics are still on the fence about these tests.


One thing’s crystal clear: the longevity market isn’t just simmering – it’s sizzling. Investment is skyrocketing, and when tech titans and AI aficionados dive in headfirst, you know it’s not just a fleeting trend. From Silicon Valley’s elite to Wall Street’s wizards, all eyes are on this nascent sector.

We’re witnessing the dawn of a new era, where the boundaries of life, tech, and investment intertwine.

So, buckle up.

The Longr Reads Team.


“There are more than 1 billion people aged 60 years and older in the world today – enough to populate an entire 7th Continent”

Aging Analytics


Longr Reads’ of the Week

  • How long can we live? (NYTM)
  • How longevity will reboot health, wellness, and the economy (Forbes)
  • Firms could extend employees’ lifespan by ~ 12 years (Deloitte)
Latest
Follow Us
The latest thinking on what matters most in longevity
Sign up for our newsletter

We value your privacy. Your email address will only be used to send you our newsletter and will not be shared with any third parties. You can unsubscribe at any time.

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic.